Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease

Creative Commons License

Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Kabacam G., ...Daha Fazla

JOURNAL OF INFECTIOUS DISEASES, cilt.217, sa.8, ss.1184-1192, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 217 Sayı: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1093/infdis/jix656
  • Dergi Adı: JOURNAL OF INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1184-1192
  • Anahtar Kelimeler: Hepatitis B, interferon treatment, hepatocellular carcinoma, liver-related mortality, HBsAg clearance, HIV-INFECTED PATIENTS, HDV RNA RELAPSE, PEGYLATED INTERFERON-ALPHA-2B, COINFECTED PATIENTS, ALPHA THERAPY, VIRUS, TENOFOVIR, EFFICACY, REPLICATION, COMBINATION
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. Interferon is the only treatment option in chronic delta hepatitis (CDH). A CDH database (333 patients, 161 with interferon treatment history) was analyzed for effects of treatment duration on virologic response and clinical outcomes.